The impact of irregularly rising prostate-specific antigen and 'impending failure' on the apparent outcome of localized prostate cancer following radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 4, 2001, Pages 957-963

  Hodgson, D C ^a   Catton, C N ^a   Warde, P ^a   Gospodarowicz, M K ^a   Milosevic, M F ^a   McLean, M ^a   Catton, P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Prostate specific antigen; Prostatic neoplasms; Radiotherapy; Treatment outcome

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; RELAPSE; STANDARD; SURVIVAL; TECHNIQUE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 0035869719     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01431-0     Document Type: Article

References (29)

1. PSA after definitive radiotherapy for clinically localized prostate cancer
2. Prostate specific antigen after external beam radiotherapy for prostatic cancer; Followup
3. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate; New insights into outcome from repeat biopsy and prostate specific antigen followup
4. Localized prostate cancer treated by external-beam radiotherapy alone; Serum prostate-specific antigen-driven outcome analysis
5. Consensus statement; Guidelines for PSA following radiation therapy
6. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
7. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
8. Radiation therapy for clinically localized prostate cancer; A multi-institutional pooled analysis
9. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology
10. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy
11. The treatment of prostate cancer by conventional radiation therapy. An analysis of long-term outcome
12. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma
13. Phase III trial of androgen suppression using goserelin in unfavorable- prognosis carcinoma of the prostate treated with definitive radiotherapy. Report of Radiation Therapy Oncology Group Protocol 85-31
14. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma; A randomized comparative trial of the Radiation Therapy Oncology Group
15. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
16. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer; Prognostic implications
17. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
18. Prostate specific antigen nadir following external beam radaition therapy for clinically localized prostate cancer; The relationship between nadir level and disease-free survival
19. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy
20. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
21. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma
22. PSA relapse definitions-The Vancouver Rules show superior predictive power
23. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy
24. Dose escalation with 3D conformal treatment; Five year outcomes, treatment optimization, and future directions
25. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology
26. Dose escalation with 3D conformal treatment; five year outcomes, treatment optimization, and future directions
27. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
28. Preliminary results of a randomized does-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer (Abstr)
29. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer